Deuterated compounds and uses thereof
US-10675367-B2 · Jun 9, 2020 · US
Deuterated compounds
US11504440B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11504440-B2 |
| Application number | US-202016895352-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 8, 2020 |
| Priority date | May 13, 2014 |
| Publication date | Nov 22, 2022 |
| Grant date | Nov 22, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V):and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
First claim
Opening claim text (preview).
We claim: 1. A compound selected from: and salts thereof, wherein X is bromine, hydroxy or a toluenesulfonyl group, and wherein each deuterated position has a deuterium isotopic enrichment factor of at least 3500. 2. A compound according to claim 1 , wherein X is bromine or hydroxy, and salts thereof. 3. A compound according to claim 1 , wherein X is hydroxy, and salts thereof. 4. A compound according to claim 1 , which is wherein X is bromine or hydroxy, and salts thereof. 5. A compound according to claim 1 , which is and salts thereof. 6. A compound according to claim 5 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 4000. 7. A compound according to claim 5 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 4500. 8. A compound according to claim 5 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 5000. 9. A compound according to claim 5 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 5500. 10. A compound according to claim 5 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 6000. 11. A compound according to claim 5 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 6600. 12. A compound according to claim 1 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 4000. 13. A compound according to claim 1 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 4500. 14. A compound according to claim 1 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 5000. 15. A compound according to claim 1 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 5500. 16. A compound according to claim 1 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 6000. 17. A compound according to claim 1 , wherein each deuterated position has a deuterium isotopic enrichment factor of at least 6600.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Heterocyclic compounds · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
- A61K51/0459Primary
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11504440B2 cover?
- The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V):and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K51/0459. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).